These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26335016)

  • 1. Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Valentino F; Cosentino G; Fierro B; Realmuto S; Mastrilli S; Savettieri G; D'Amelio M
    Neurol Sci; 2015 Dec; 36(12):2305. PubMed ID: 26335016
    [No Abstract]   [Full Text] [Related]  

  • 2. Rasagiline and Pisa syndrome in Parkinson's disease patients.
    Solla P; Cannas A; Orofino G; Marrosu F
    Neurol Sci; 2015 Mar; 36(3):485-6. PubMed ID: 25481627
    [No Abstract]   [Full Text] [Related]  

  • 3. Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Valentino F; Cosentino G; Fierro B; Realmuto S; Mastrilli S; Savettieri G; D'Amelio M
    Neurol Sci; 2014 Oct; 35(10):1615-7. PubMed ID: 24770981
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
    Fasano A; Di Matteo A; Vitale C; Squintani G; Ferigo L; Bombieri F; Santangelo G; Amboni M; Barone P; Tinazzi M
    Mov Disord; 2011 Dec; 26(14):2578-80. PubMed ID: 22170277
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasagiline in Parkinson's disease: the show must go on.
    Jost WH
    Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684
    [No Abstract]   [Full Text] [Related]  

  • 6. Rasagiline induced hypersexuality in Parkinson's disease.
    Reyes D; Kurako K; Galvez-Jimenez N
    J Clin Neurosci; 2014 Mar; 21(3):507-8. PubMed ID: 24055209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
    Titova NV; Katunina EA; Sotnikova NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):90-99. PubMed ID: 27386592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of rasagiline-induced spontaneous orgasms in a female patient.
    Uca AU; Kozak HH
    Parkinsonism Relat Disord; 2014 Aug; 20(8):929-30. PubMed ID: 24837642
    [No Abstract]   [Full Text] [Related]  

  • 9. Rasagiline: a review of its use in the management of Parkinson's disease.
    Oldfield V; Keating GM; Perry CM
    Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
    Vitale C; Santangelo G; Erro R; Errico D; Manganelli F; Improta I; Moccia M; Barone P
    Parkinsonism Relat Disord; 2013 Apr; 19(4):483-4. PubMed ID: 23305965
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe off-period facial dystonia in Parkinson's disease.
    Miranda M; Chaná P
    Mov Disord; 2000 Jan; 15(1):163-4. PubMed ID: 10634259
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.